YAP1 and cancer: Multiple preclinical data generated from cell line-derived xenografts (CDX) showed that TEAD inhibitors, including the recently developed leads (VT3989, IK-930, IAG933, and BPI-460372), are efficacious in YAP/TAZ-dependent cancer types.